RAC 0.60% $1.69 race oncology ltd

General Comments / Chat, page-4808

  1. 2,846 Posts.
    lightbulb Created with Sketch. 3487
    Assuming the EM AML trial is pending CDX patent submissions.

    The reason for the change in tact regarding breast cancer is that preclinical data determined Zantrene makes doxorubicin more effective. Why compete with an established market when you can improve it?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.69
Change
0.010(0.60%)
Mkt cap ! $287.1M
Open High Low Value Volume
$1.69 $1.70 $1.65 $89.01K 53.2K

Buyers (Bids)

No. Vol. Price($)
1 2342 $1.69
 

Sellers (Offers)

Price($) Vol. No.
$1.70 5 1
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.